Skip to main content

Clinical Trials Using Fulvestrant

Review the clinical trials studying fulvestrant on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 58

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Status: Active
Location: 4 locations
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Status: Active
Location: 4 locations
SNV4818 in Participants With Advanced Solid Tumors
Status: Active
Location: 3 locations
Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
Status: Active
Location: 3 locations
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Status: Active
Location: 3 locations
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Status: Active
Location: 3 locations
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Status: Active
Location: 4 locations
Study of INCB123667 in Subjects With Advanced Solid Tumors
Status: Active
Location: 3 locations
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Status: Active
Location: 4 locations
Stereotactic Radiosurgery, Abemaciclib, and Endocrine Therapy for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases
Status: Active
Location: 2 locations
Abemaciclib, Avutometinib, and Fulvestrant for the Treatment of Metastatic or Locally Recurrent Hormone Receptor Positive/HER2 Negative Breast Cancer
Status: Active
Location: 2 locations
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Status: Active
Location: 3 locations
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Status: Active
Location: 2 locations
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
Status: Active
Location: 2 locations
Nab-Sirolimus and Fulvestrant for the Treatment of Recurrent Low Grade Serous Ovarian Cancer
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Fulvestrant and Neratinib, Alpelisib, Everolimus or Abemaciclib for the Treatment of Estrogen Receptor Positive HER2 Negative Metastatic or Locally Recurrent Breast Cancer Previously Treated with a CDK4/6 Inhibitor, GERTRUDE Trial
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Anastrozole, Fulvestrant, and Abemaciclib for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Status: Active
Location: 3 locations
A Sequential Treatment Plan for the Treatment of Hormone Positive Metastatic Breast Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Status: Active
Location: University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
177Lu-DOTATATE and Fulvestrant for the Treatment of Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Avasopasem for the Treatment of Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer with Progression on a CDK4/6 Inhibitor and Hormonal Therapy
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas